Latest news with #DeviceSolutions
Yahoo
15-05-2025
- Business
- Yahoo
ITRI Q1 Earnings Call: Margin Expansion and Software Growth Offset Revenue Miss
Resource management provider Itron (NASDAQ:ITRI) missed Wall Street's revenue expectations in Q1 CY2025, with sales flat year on year at $607.2 million. On the other hand, the company expects next quarter's revenue to be around $610 million, close to analysts' estimates. Its non-GAAP profit of $1.52 per share was 15.3% above analysts' consensus estimates. Is now the time to buy ITRI? Find out in our full research report (it's free). Revenue: $607.2 million vs analyst estimates of $614.1 million (flat year on year, 1.1% miss) Adjusted EPS: $1.52 vs analyst estimates of $1.32 (15.3% beat) Adjusted EBITDA: $87.93 million vs analyst estimates of $83.5 million (14.5% margin, 5.3% beat) Revenue Guidance for Q2 CY2025 is $610 million at the midpoint, roughly in line with what analysts were expecting Adjusted EPS guidance for Q2 CY2025 is $1.35 at the midpoint, above analyst estimates of $1.29 Operating Margin: 12.6%, up from 10.4% in the same quarter last year Free Cash Flow Margin: 11.1%, up from 5.7% in the same quarter last year Market Capitalization: $5.19 billion Itron's first quarter performance was shaped by favorable shifts in product mix and continued operational execution, as highlighted by CEO Tom Deitrich. The company saw expansion of gross margins and operating efficiency, particularly due to disciplined manufacturing and customer demand for its grid edge intelligence platform. CFO Joan Hooper pointed to record margins in Device Solutions and improved recurring revenue in Outcomes as supporting factors for margin growth, despite revenue coming in flat compared to the prior year. Looking ahead, management noted that expected tariff impacts and a stable demand environment are key themes for the remainder of the year. Deitrich acknowledged the fluid tariff landscape, estimating a $15 million EBITDA effect for 2025, but emphasized that mitigation strategies and ongoing supply chain adjustments should help maintain margin strength. Hooper added that recurring software revenue and disciplined capital allocation remain top priorities as Itron navigates macroeconomic and trade uncertainties. First quarter performance was driven by a favorable product mix, margin expansion, and continued demand for advanced grid intelligence solutions. Management emphasized operational discipline, recurring software growth, and resilience to evolving trade policies. Margin Expansion Through Product Mix: Gross margin reached a quarterly record, supported by a shift toward higher-margin products in Device Solutions and Outcomes. Portfolio pruning and a move away from legacy electric offerings contributed to improved profitability. Software and Recurring Revenue Growth: Outcomes segment revenue grew 14% year-over-year, with management highlighting four consecutive quarters of double-digit growth. Recurring software licenses made up approximately 70% of Outcomes revenue, with an ultimate goal of reaching 80%. Grid Edge Platform Adoption: Customer adoption of Itron's distributed intelligence and grid edge platforms continued, with 14.4 million endpoints shipped and another 10 million-plus in backlog. Key utility projects—including those with FirstEnergy and Public Service Company of New Mexico—drove demand for solutions that enhance outage detection and infrastructure agility. Tariff and Supply Chain Management: The company's regional supply strategy, including significant manufacturing in the U.S. and USMCA-compliant sourcing from Mexico, is helping to mitigate tariff impacts. Management estimates a $15 million net EBITDA impact from current tariffs for 2025, with most of the cost expected in the second half of the year. Constructive Regulatory Environment: Management described a supportive regulatory backdrop for utility software purchases, with the majority of states enabling rate-base inclusion for software and performance-based rates, facilitating ongoing Outcomes segment growth. Management's outlook for the next quarter and the remainder of the year centers on navigating tariff headwinds, sustaining margin improvements, and driving recurring software revenue growth, while acknowledging macroeconomic and regulatory uncertainties. Tariff Impact Mitigation: Itron is focused on offsetting anticipated tariff impacts through regional manufacturing, sourcing flexibility, and selective pricing adjustments, aiming to minimize disruption to margins and profitability. Recurring Revenue Expansion: Strategic emphasis remains on growing the Outcomes software segment, with management targeting a higher proportion of recurring revenue and ongoing margin expansion through product mix and operational leverage. Stable Utility Demand: The company sees steady customer demand for infrastructure modernization and grid intelligence solutions, although management noted that broader macroeconomic shifts could affect order timing or project execution later in the year. Noah Kaye (Oppenheimer): Asked if tariff headwinds would alter full-year guidance; management said it is too early to update, but current mitigation keeps guidance on track. Ben Kallo (R.W. Baird): Questioned regulatory progress on utilities capitalizing software; Tom Deitrich pointed to positive trends and mechanisms in most states enabling inclusion in rate bases. Jeff Osborne (TD Cowen): Inquired about the timing of tariff cost impacts and CapEx implications; management expects most tariff costs in the year's second half and no material change to capital expenditures. Joe Osha (Guggenheim): Sought clarity on margin sustainability in Outcomes after strong results; Joan Hooper said margins will fluctuate with software mix but expects year-over-year margin growth. Chip Moore (ROTH Capital Partners): Asked about capital allocation priorities; Joan Hooper indicated acquisitions to expand software capabilities are the top focus, with active exploration of potential deals. In the coming quarters, the StockStory team will closely monitor (1) the pace of recurring revenue growth in the Outcomes segment, (2) the effectiveness of tariff mitigation strategies as new trade measures are implemented, and (3) ongoing customer adoption of Itron's grid edge and distributed intelligence solutions. We will also watch for updates on potential software-focused acquisitions, which could accelerate recurring revenue and margin expansion. Itron currently trades at a forward P/E ratio of 20.7×. Should you double down or take your chips? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Yahoo
03-05-2025
- Business
- Yahoo
Itron Inc (ITRI) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strong Cash Flow ...
Revenue: $607 million, increased 1% year-over-year. Adjusted EBITDA: $88 million, increased 15% with a margin of 14.5%. Non-GAAP Earnings Per Share: $1.52, up from $1.24 a year ago. Free Cash Flow: $67 million, compared to $34 million a year ago. Gross Margin: 35.8%, a quarterly record, up 180 basis points year-over-year. GAAP Net Income: $65 million or $1.42 per diluted share, compared to $52 million or $1.12 per share last year. Bookings: $530 million, with a book-to-bill ratio of 0.9 to 1. Backlog: $4.7 billion at quarter end. Device Solutions Revenue: $126 million, gross margin of 30%, operating margin of 24.2%. Network Solutions Revenue: $403 million, gross margin of 36.9%, operating margin of 28.8%. Outcomes Revenue: $79 million, gross margin of 39.2%, operating margin of 18.2%. Total Debt: $1.265 billion, net debt of $142 million. Cash and Equivalents: $1.1 billion. Second Quarter Revenue Outlook: $605 million to $615 million. Second Quarter Non-GAAP EPS Outlook: $1.30 to $1.40 per diluted share. Warning! GuruFocus has detected 3 Warning Sign with ITRI. Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Itron Inc (NASDAQ:ITRI) reported a strong first quarter with revenue of $607 million, adjusted EBITDA of $88 million, and non-GAAP earnings per share of $1.52. The company achieved a record gross margin of 35.8%, driven by favorable product mix and operational efficiencies. Itron Inc (NASDAQ:ITRI) has a robust backlog of $4.7 billion, with Network Solutions and Outcomes segments representing over 95% of total bookings. The company continues to see strong customer demand for its grid edge intelligence platform, enhancing infrastructure agility and reliability. Itron Inc (NASDAQ:ITRI) reported a significant increase in free cash flow to $67 million, reflecting strong operational earnings growth and improved working capital. Bookings for the first quarter were $530 million, resulting in a book-to-bill ratio of 0.9, which may indicate a potential slowdown in future revenue growth. The tariff environment remains dynamic, with an estimated EBITDA impact of $15 million for the year, which could affect profitability. Device Solutions revenue decreased by 1% year-over-year, indicating potential challenges in this segment. The company faces macroeconomic and trade policy uncertainties, which could impact future demand and financial performance. Despite strong performance, Itron Inc (NASDAQ:ITRI) has not updated its full-year guidance, indicating potential caution regarding future market conditions. Q: Given the strength of Q1 and expectations for Q2, are you comfortable with the full-year guidance despite the tariff impacts? A: Thomas Deitrich, CEO, mentioned it's premature to update full-year guidance. While Q1 and Q2 are ahead of expectations, the tariff situation remains dynamic, and they will reassess after Q2 earnings. Joan Hooper, CFO, added that the first half EPS is up 10% versus consensus, indicating a strong start to the year. Q: How should we think about the segment margins for devices going forward, given the record margins achieved? A: Joan Hooper, CFO, stated that while it's premature to update long-term targets, they are pleased with the progress. The mix shift and portfolio pruning have contributed to the strong margins, but variability is expected quarter-to-quarter. Q: Can you provide insights into the regulatory environment for capitalizing software in the rate base? A: Thomas Deitrich, CEO, explained that the regulatory environment is constructive, with mechanisms varying by state. Performance-based rates are becoming more common, and the company structures deals to align with customer business plans, supporting continued growth in software sales. Q: What is the impact of tariffs on your financials, and how are you mitigating these effects? A: Thomas Deitrich, CEO, noted that the $15 million EBITDA impact includes current tariffs and mitigation measures like alternate sourcing and pricing adjustments. The impact is expected to be more pronounced in the latter half of the year. Q: How do your grid edge intelligence solutions assist in blackout situations like the recent one in Spain and Portugal? A: Thomas Deitrich, CEO, highlighted that their solutions provide visibility and control at the grid edge, aiding in segmentation, microgrid solutions, and demand response. These capabilities help minimize damage and restore power more quickly during outages. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Korea Herald
30-04-2025
- Business
- Korea Herald
Samsung Electronics beats Q1 estimates, but chip woes persist
Chip division posts third straight decline as tech giant braces for potential US tariffs Samsung Electronics on Wednesday reported a stronger-than-expected earnings for the first quarter, buoyed by robust sales of its AI-enhanced Galaxy S25 smartphones, even as its key chip division continues to tumble. For the January-March period, the tech giant posted an operating profit of 6.69 trillion won ($4.69 billion), up 1.2 percent from a year earlier. The figure exceeded analysts' expectations, which had hovered in the 5 trillion-won range. Revenue for the quarter came to 79.14 trillion won, up 10.05 percent on-year, marking an all-time quarterly high. Net profit climbed 21.7 percent to 8.22 trillion won from the same period last year. The upbeat results came despite persistent woes in the critical semiconductor segment. The company's chip division, the Device Solutions unit, posted an operating profit of 1.1 trillion won, down 0.8 percent on-year, and marked the third consecutive quarter of declining performance. Its sales slumped 17 percent to 25.1 trillion won, due to a drop in sales of the key high-bandwidth memory chips. While demand for DRAM and NAND sales improved during the period as customers anticipated a price rebound, the overall gains were dampened by weak HBM sales, which were impacted by US export controls on AI chips. In a conference call, Kim Jae-joon, executive vice president of the DS division, told investors that the company is expected to see its sales rebound as it expands the supply of improved 12-layer HBM3E AI chips to clients. 'We have completed supplying samples of the improved HBM3E products to our major clients, and we expect to see more companies purchase from the second quarter,' Kim said. 'Sales of HBM have hit bottom in the first quarter, but are expected to recover gradually, quarter by quarter.' Samsung is still waiting to secure Nvidia's green light for its HBM chips -– a critical component for the GPUs that power generative AI systems like ChatGPT. Samsung's failure to secure an earlier edge against its smaller crosstown rival SK hynix has continued to weigh on its earnings and wiped out billions of dollars of market value last year. The company's struggling contract chip manufacturing, or foundry unit, underperformed due to weak seasonal demand, especially in mobile phones, and client inventory adjustment and stagnant fab utilization. Meanwhile, the company's Device Experience division, responsible for smartphones, mobile devices, TVs and other consumer electronics, saw its sales jump 28 percent on-year to 51.7 trillion won and an operating profit of 4.7 trillion won. Leading the sales was the mobile business, which alone posted 37 trillion won in sales and 4.3 trillion won in operating profit. The Galaxy S25 series, which was launched in February, has set a new domestic record by surpassing 1 million units sold in the shortest time for any Galaxy model in South Korea. Looking ahead, company executives expressed caution as the US tariffs could pose uncertainty for its chip businesses and smartphone components. 'We are closely monitoring trade policies in key markets and maintaining close communication to minimize negative impact,' Park Soon-cheol, Samsung's chief financial officer, told investors during a conference call. 'We will make the most of our global production base and customer management capabilities to respond swiftly as needed.' Park acknowledged the challenges of scenario planning amid rapidly changing tariff policies and geopolitical tensions. To minimize exposure, Park said Samsung will consider relocating production of certain home appliance volumes, while expanding premium product lines. He also added that if tariffs are imposed on semiconductors, the mobile division will offset potential price hikes by expanding its flagship and new Edge model sales. 'As for the DS division, we will closely monitor the direction of the US semiconductor tariff policy and continue to review response plans based on various scenarios,' he said.
Associated Press
04-03-2025
- Business
- Associated Press
InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024
InfuSystem Holdings, Inc. (NYSE American: INFU), ('InfuSystem' or the 'Company'), a leading national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Overview: Net revenues totaled $33.8 million, an increase of 7% vs. prior year. Patient Services net revenue was $20.8 million, an increase of 8% vs. prior year. Device Solutions net revenue was $13.1 million, an increase of 4% vs. prior year. Gross profit was $18.2 million, an increase of 9% vs. prior year. Gross margin was 53.8%, an increase of 1.2% vs. prior year. Operating income was $2.6 million, an increase of 109% vs. prior year. Net income of $0.9 million, or $0.04 per diluted share. Adjusted earnings before interest, income taxes, depreciation, and amortization ('Adjusted EBITDA') (non-GAAP) was $7.5 million, an increase of 22% vs. prior year. Adjusted EBITDA margin was 22.2%, an increase of 2.8% vs. prior year. Net cash provided by operations was $7.9 million, an increase of 70% vs. prior year. Full Year Overview: Net revenues totaled $134.9 million, an increase of 7% vs. prior year. Patient Services net revenue was $80.4 million, an increase of 5% vs. prior year. Device Solutions net revenue was $54.5 million, an increase of 11% vs. prior year. Gross profit was $70.4 million, an increase of 12% vs. prior year. Gross margin was 52.2%, an increase of 2.0% vs. prior year. Operating income was $6.9 million, an increase of 69% vs. prior year. Net income of $2.3 million, an increase of $1.5 million. Earnings per share of $0.11 per diluted share vs. $0.04 per diluted share in the prior year. Adjusted EBITDA was $25.3 million, an increase of 13% vs. prior year. Adjusted EBITDA margin was 18.8%, an increase of 1.0% vs. prior year. Net cash provided by operations was $20.5 million, an increase of 82% vs. prior year. Company liquidity totaled $51.4 million, as of December 31, 2024. Management Discussion Richard DiIorio, Chief Executive Officer of InfuSystem, said, 'Our financial results in 2024 came in consistent with our plan. At the start of the year, we announced that after a strong growth year in 2023, our priority in 2024 would be continuous process improvements that would increase our operating margins and long-term profit potential. We can report that we delivered on that priority. Compared to the prior year gross margins improved by 2% to 52.2%, operating income increased by 69% to $6.9 million, and Adjusted EBITDA rose 13% to $25.3 million. The Adjusted EBITDA margin percentage was 18.8% representing a 1.0% improvement over 2023, in line with our guidance even with the inclusion of $735 thousand of technology systems upgrade costs that were not included in our original forecast for the year.' 'Our revenue growth for the full year 2024 was 7.2%, taking us to $134.9 million', continued Mr. DiIorio. 'That result was slightly below expectations and due to delays in onboarding a new wound care initiative as we paused to improve our referral processes with some new partners. Away from the effects of that delay, we saw growth across the board last year, with oncology and pain management growing by 6.1% and 14.7%, respectively. In our Device Solutions unit, equipment rentals grew by 13.5%, equipment sales by 20.6%, driven by a large one-time transaction in the third quarter, and biomed grew by 6.7%.' 'Prospects for continuing and future growth were improved in 2024 with new customer relationships in both wound care and biomedical services and new products that leverage core strengths in our existing markets. As we previously reported, during 2024 we entered into a new distribution agreement with Smith+Nephew, a global leader in medical technology. This collaboration expands our portfolio of medical equipment and increases our opportunities in wound care. Another accomplishment was the previously reported execution of an exclusive United States distribution agreement with ChemoMouthpiece, LLC ('ChemoMouthpiece') through SI Healthcare Technologies, LLC, our joint venture with Sanara MedTech Inc. The ChemoMouthpiece is an oral cryotherapy device, bringing potential relief to thousands of cancer patients suffering from oral mucositis.' 'In addition to the significant new growth potential as we transition our business beyond oncology to broader device solutions, we are excited by the rapidly increasing capital efficiency of our business. This is being driven by both by the lower capital spending requirements of continuing growth in wound care and biomed, and by the steadily improving utilization rates of our device fleet. The net benefit is rising free cash flows that allowed for significant debt repayments bringing net debt at the end of 2024 down by approximately $5 million from the prior year. In addition, the Company executed stock repurchases totaling $1.2 million during fiscal 2024 and in the first quarter of 2025, we executed a block purchase of approximately $2.4 million,' concluded Mr. DiIorio. 'As we look to 2025, we are expecting revenue growth to come in between 8% to 10% and our Adjusted EBITDA to increase at a faster rate, again demonstrate the leverage in our business. This will take our Adjusted EBITDA margin above the 18.8% delivered in 2024. This is inclusive of the impact of costs related to our ongoing information technology systems upgrade, for which expenses are expected to be approximately $2.5 million in 2025. Without the impact of this program, which is expected to be largely completed this year, our outlook for 2025 would be for Adjusted EBITDA margins above 20%. Our business is generally subject to a seasonal cycle, particularly with respect to certain expenses incurred in the first quarter, which results in materially lower Adjusted EBITDA and cash flow numbers relative to the subsequent three quarters. Sequential revenue growth is also generally less in the first quarter, due in part to the annual resetting of patient insurance deductibles. We will look to update and refine our guidance as we move throughout the year,' concluded Mr. DiIorio. 2024 Fourth Quarter Financial Review Net revenues for the quarter ended December 31, 2024 were $33.8 million, an increase of $2.1 million, or 7%, compared to $31.8 million for the quarter ended December 31, 2023. The increase was attributable to both the Patient Services and Device Solutions Segments. Patient Services net revenue of $20.8 million increased $1.6 million, or 8%, during the fourth quarter of 2024 as compared to the same prior year period. This increase was primarily attributable to additional treatment volume totaling $1.8 million offset partially by lower revenue from sales-type leases of NPWT pumps. The improved volume increases benefited the Oncology revenue by $0.9 million, or 5%, Pain Management revenue by $0.3 million, or 28%, and Wound Care treatment revenue by $0.5 million, or 449%, compared to the same prior year period. Device Solutions net revenue of $13.1 million increased $0.5 million, or 4%, during the fourth quarter of 2024 as compared to the prior year period. This increase included higher rental and disposable medical supplies revenue of $1.0 million and $0.1 million, respectively, representing increases of 22% and 5.6%, respectively. These increases were partially offset by lower biomedical services revenue, which decreased by $0.5 million, or 12.9%. The increases in rental revenue and disposables are mainly attributable to new customers added during 2024. The lower Biomedical services partially reflected down time related to the holidays and large project timing. Gross profit for the fourth quarter of 2024 of $18.2 million increased $1.5 million, or 9%, from $16.7 million for the fourth quarter of 2023. The increase was driven by the increase in net revenues and by a higher gross profit as a percentage of net revenue (i.e., gross margin). Gross margin was 53.8% during the fourth quarter of 2024 as compared to 52.6% during the same prior year period, an increase of 1.2%. Gross profit increased in both the Patient Services and Device Solutions segments. Gross margin increased in the Device Solutions segment, but was lower in the Patient Services segment. Patient Services gross profit was $13.4 million during the fourth quarter of 2024, representing an increase of $0.8 million compared to the same prior year period. The improvement reflected an increase in net revenues offset partially by a lower gross margin, which decreased from the same prior year period by 1.0% to 64.6%. The lower gross margin was the result of unfavorable product mix favoring lower margin therapies and higher device maintenance expenses. Device Solutions gross profit during the fourth quarter of 2024 was $4.8 million, representing an increase of $0.7 million, or 16%, compared to the same prior year period. This increase was due to higher net revenue and higher gross margin. The Device Solutions gross margin was 36.7% during the current quarter, which was 3.9% higher than the prior year. This increase was due to a favorable product mix favoring higher margin rental revenues. Selling and marketing expenses for the fourth quarter of 2024 were $2.1 million, representing a decrease of $1.6 million, or 42%, as compared to the fourth quarter of 2023. Selling and marketing expenses as a percentage of net revenues during 2024 was 6.3% representing a decrease of 5.4% compared to the prior year period. This decrease was mainly attributable to a reduction in sales commissions and a reduction in sales team members. Lower commission rates reflected the slower sales growth in 2024 as compared to 2023. General and administrative ('G&A') expenses for the fourth quarter of 2024 were $13.2 million, an increase of 15% from $11.5 million for the fourth quarter of 2023. The increase of $1.7 million included $0.4 million of expenses not incurred in 2023 related to a project to upgrade the Company's information technology and business applications and an increase in management short-term incentive bonus expense of $0.4 million. Other increased expenses totaling $0.9 million were associated with revenue volume growth including the cost of additional personnel, information technology and general business expenses and included inflationary increases. General and administrative expenses as a percentage of net revenues increased by 2.8% to 39.0% compared to 36.2% in the prior year period. Net income for the fourth quarter of 2024 was $0.9 million, or $0.04 per diluted share, compared to $0.1 million, or $0.00 per diluted share for the fourth quarter of 2023. Adjusted EBITDA, a non-GAAP measure, for the fourth quarter of 2024 was $7.5 million, or 22.2% of net revenue, and increased by $1.3 million, or 21.9%, compared to Adjusted EBITDA for the same prior year quarter of $6.2 million, or 19.4% of prior period net revenue. Balance sheet, cash flows and liquidity During the year ended December 31, 2024, operating cash flow increased to $20.5 million, a $9.2 million or 82% increase as compared to operating cash flow during the same prior year period. The increase was primarily due to lower working capital levels and higher operating margins during the period. Capital expenditures, which include purchases of medical devices, totaled $17.8 million during the year ended December 31, 2024, which was $6.7 million, or 60%, higher than the amount purchased during 2023. This increase reflected the revenue growth during 2024, which favored products, such as Oncology, Pain Management and Rental revenues, that require the purchase of medical devices. Offsetting capital expenditures were proceeds from the sale of medical equipment totaling $4.6 million during 2024 and $4.4 million during 2023. As of December 31, 2024, available liquidity for the Company totaled $51.4 million and consisted of $50.9 million in available borrowing capacity under the new revolving line of credit plus cash and cash equivalents of $0.5 million. Net debt, a non-GAAP measure (calculated as total debt of $23.9 million less cash and cash equivalents of $0.5 million) as of December 31, 2024 was $23.3 million representing a decrease of $5.5 million as compared to net debt of $28.9 million as of December 31, 2023 (calculated as total debt of $29.1 million less cash and cash equivalents of $0.2 million). Our ratio of Adjusted EBITDA to net debt (non-GAAP) for the last four quarters was 0.92 to 1.00 (calculated as net debt of $23.3 million divided by Adjusted EBITDA of $25.3 million). We maintain a low balance of cash in our bank accounts to achieve maximum cash efficiency due to the fact that our bank debt is an all-revolver facility which allows us to use any excess operating cash to pay down our revolving lines each day. Fiscal Year 2025 Guidance InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year. The full year 2025 guidance reflects management's current expectation for operational performance, given the current market conditions. This includes our best estimate of revenue and Adjusted EBITDA. The Company and its businesses are subject to certain risks, including those risk factors discussed in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed on April 10, 2024. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Conference Call The Company will conduct a conference call for all interested investors on March 4, 2025, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The call will include discussion of Company developments, forward-looking statements and other material information about business and financial matters. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company's website at A replay of the call will be available by visiting for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, replay access code 9301008, through Tuesday, March 11, 2025. Non-GAAP Measures This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. Non-GAAP financial measures presented in this press release include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, net debt and Adjusted EBITDA to net debt ratio. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring or non-core items that are not part of the normal course of business. A reconciliation of those measures to the most directly comparable GAAP measures is provided in the accompanying schedule, titled 'GAAP to Non-GAAP Reconciliation' below. Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the accompanying schedule below. Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as non-core, nonrecurring, unusual or unanticipated changes, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures and, therefore, such comparable GAAP measures and reconciliations are excluded from this release in reliance upon applicable SEC staff guidance. About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. (NYSE American:INFU), is a leading national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. Forward-Looking Statements The financial results in this press release reflect preliminary results, which are not final until the Company ' s annual report on Form 10-K for the year ended December 31, 2024 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words ' believe, ' ' may, ' ' will, ' ' estimate, ' ' continue, ' ' anticipate, ' ' intend, ' ' should, ' ' plan, ' ' goal, ' ' expect, ' ' strategy, ' ' future, ' ' likely, ' variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, the uncertain impact of disruptions caused by public health emergencies or extreme weather or other climate change-related events, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company's ability to remediate any material weaknesses in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company ' s most recent Annual Report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law. FINANCIAL TABLES FOLLOW INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended D ecember 31, Years Ended D ecember 31, (in thousands, except share and per share data) 2024 2023 2024 2023 Net revenues $ 33,848 $ 31,771 $ 134,861 $ 125,785 Cost of revenues 15,632 15,060 64,458 62,676 Gross profit 18,216 16,711 70,403 63,109 Selling, general and administrative expenses: Amortization of intangibles 248 247 991 990 Selling and marketing 2,139 3,717 11,312 12,654 General and administrative 13,213 11,497 51,209 45,377 Total selling, general and administrative 15,600 15,461 63,512 59,021 Operating income 2,616 1,250 6,891 4,088 Other expense: Interest expense (361 ) (503 ) (1,777 ) (2,170 ) Other income (expense) 9 (20 ) (55 ) (67 ) Income before income taxes 2,264 727 5,059 1,851 Provision for income taxes (1,331 ) (655 ) (2,714 ) (979 ) Net income $ 933 $ 72 $ 2,345 $ 872 Net income per share Basic $ 0.04 $ — $ 0.11 $ 0.04 Diluted $ 0.04 $ — $ 0.11 $ 0.04 Weighted average shares outstanding: Basic 21,270,864 21,189,579 21,271,608 21,024,382 Diluted 21,736,178 21,758,959 21,707,151 21,646,079 INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS SEGMENT REPORTING (UNAUDITED) Three Months Ended D ecember 31, Better/ (Worse) (in thousands) 2024 2023 Net revenues: Patient Services $ 20,761 $ 19,159 $ 1,602 Device Solutions (inclusive of inter-segment revenues) 14,894 14,284 610 Less: elimination of inter-segment revenues (1,807 ) (1,672 ) (135 ) Total 33,848 31,771 2,077 Gross profit (inclusive of certain inter-segment allocations) (a): Patient Services 13,414 12,577 837 Device Solutions 4,802 4,134 668 Total $ 18,216 $ 16,711 $ 1,505 (a) Inter-segment allocations are for cleaning and repair services performed on medical equipment. Years Ended D ecember 31, Better/ (Worse) (in thousands) 2024 2023 Net revenues: Patient Services $ 80,378 $ 76,541 $ 3,837 Device Solutions (inclusive of inter-segment revenues) 61,737 55,825 5,912 Less: elimination of inter-segment revenues (7,254 ) (6,581 ) (673 ) Total 134,861 125,785 9,076 Gross profit (inclusive of certain inter-segment allocations) (a): Patient Services 52,842 47,800 5,042 Device Solutions 17,561 15,309 2,252 Total $ 70,403 $ 63,109 $ 7,294 (a) Inter-segment allocations are for cleaning and repair services performed on medical equipment. INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION (UNAUDITED) NET INCOME TO EBITDA, ADJUSTED EBITDA, NET INCOME MARGIN AND ADJUSTED EBITDA MARGIN: Three Months Ended D ecember 31, Years Ended D ecember 31, (in thousands) 2024 2023 2024 2023 GAAP net income $ 933 $ 72 $ 2,345 $ 872 Adjustments: Interest expense 361 503 1,777 2,170 Income tax provision 1,331 655 2,714 979 Depreciation 3,173 2,897 11,508 11,518 Amortization 248 247 991 990 Non-GAAP EBITDA $ 6,046 $ 4,374 $ 19,335 $ 16,529 Stock compensation costs 1,184 1,275 4,460 4,074 Medical equipment reserve (1) 205 428 573 1,501 Management reorganization/transition costs — — 108 72 Cooperation Agreement payment and associated legal expenses — 16 649 16 Certain other non-recurring costs 66 60 175 174 Non-GAAP Adjusted EBITDA $ 7,501 $ 6,153 $ 25,300 $ 22,366 GAAP Net Revenues $ 33,848 $ 31,771 $ 134,861 $ 125,785 Net Income Margin (2) 2.8 % 0.2 % 1.7 % 0.7 % Non-GAAP Adjusted EBITDA Margin (3) 22.2 % 19.4 % 18.8 % 17.8 % Business Application ('ERP') Upgrade Investment (4) $ 440 — $ 735 — (1) Amounts represent a non-cash expense recorded to adjust the reserve for missing medical equipment and is being added back due to its similarity to depreciation. (2) Net Income Margin is defined as GAAP Net Income as a percentage of GAAP Net Revenues. (3) Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues. (4) Represents expenses associated with a project to upgrade the Company's information technology and business applications including a replacement of our main enterprise resource planning ('ERP') application. The project was launched during the second quarter of 2024 and is expected to be completed during the first quarter of 2026. Amounts are included in GAAP net income and have not been added back in the measurement of Non-GAAP Adjusted EBITDA. INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of (in thousands, except par value and share data) December 31, 2 024 December 31, 2 023 ASSETS Current assets: Cash and cash equivalents $ 527 $ 231 Accounts receivable, net 21,155 19,830 Inventories, net 6,528 6,402 Other current assets 3,955 4,157 Total current assets 32,165 30,620 Medical equipment for sale or rental 3,157 3,049 Medical equipment in rental service, net of accumulated depreciation 39,175 34,928 Property & equipment, net of accumulated depreciation 4,030 4,321 Goodwill 3,710 3,710 Intangible assets, net 6,456 7,446 Operating lease right of use assets 5,374 6,703 Deferred income taxes 7,188 9,115 Derivative financial instruments 1,481 1,442 Other assets 878 1,581 Total assets $ 103,614 $ 102,915 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 9,848 $ 8,009 Other current liabilities 7,813 7,704 Total current liabilities 17,661 15,713 Long-term debt, net of current portion 23,864 29,101 Operating lease liabilities, net of current portion 4,560 5,799 Total liabilities 46,085 50,613 Stockholders' equity: Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued — — Common stock, $0.0001 par value: authorized 200,000,000 shares; 21,272,351 shares issued and outstanding as of December 31, 2024, and 21,196,851 shares issued and outstanding as of December 31, 2023 2 2 Additional paid-in capital 113,868 109,837 Accumulated other comprehensive income 1,119 1,088 Retained deficit (57,460 ) (58,625 ) Total stockholders' equity 57,529 52,302 Total liabilities and stockholders' equity $ 103,614 $ 102,915 INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Years Ended December 31, (in thousands) 2024 2023 OPERATING ACTIVITIES Net income $ 2,345 $ 872 Adjustments to reconcile net income to net cash provided by operating activities: Provision for doubtful accounts (167 ) (261 ) Depreciation 11,508 11,518 Loss on disposal of and reserve adjustments for medical equipment 942 1,726 Gain on sale of medical equipment (2,268 ) (2,887 ) Amortization of intangible assets 991 990 Amortization of deferred debt issuance costs 78 120 Stock-based compensation 4,460 4,074 Deferred income taxes 1,918 633 Changes in assets - (increase)/decrease: Accounts receivable (701 ) (2,363 ) Inventories (126 ) (1,581 ) Other current assets 202 (1,235 ) Other assets 1,953 (2,798 ) Changes in liabilities - (decrease)/increase: Accounts payable and other liabilities (676 ) 2,415 NET CASH PROVIDED BY OPERATING ACTIVITIES 20,459 11,223 INVESTING ACTIVITIES Purchase of medical equipment (16,741 ) (10,093 ) Purchase of property and equipment (1,092 ) (1,024 ) Proceeds from sale of medical equipment, property and equipment 4,594 4,383 NET CASH USED IN INVESTING ACTIVITIES (13,239 ) (6,734 ) FINANCING ACTIVITIES Principal payments on long-term debt (56,113 ) (55,499 ) Cash proceeds from long-term debt 50,798 51,552 Debt issuance costs — (229 ) Common stock repurchased as part of share repurchase program (1,180 ) (153 ) Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (816 ) (1,158 ) Cash proceeds from exercise of options and ESPP 387 1,064 NET CASH USED IN FINANCING ACTIVITIES (6,924 ) (4,423 ) Net change in cash and cash equivalents 296 66 Cash and cash equivalents, beginning of period 231 165 Cash and cash equivalents, end of period $ 527 $ 231 View source version on CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN INDUSTRY KEYWORD: BIOTECHNOLOGY MANAGED CARE MEDICAL SUPPLIES GENERAL HEALTH HEALTH MEDICAL DEVICES HOSPITALS OTHER HEALTH SOURCE: InfuSystem Holdings, Inc. Copyright Business Wire 2025. PUB: 03/04/2025 06:30 AM/DISC: 03/04/2025 06:29 AM
